{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T20:23:15Z","timestamp":1781382195455,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10557-024-07585-x","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:02:13Z","timestamp":1719201733000},"page":"1215-1221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-1327","authenticated-orcid":false,"given":"Chisato","family":"Izumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoyuki","family":"Eishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Omae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"7585_CR1","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/eurheartj\/ehx141","volume":"38","author":"SJ Head","year":"2017","unstructured":"Head SJ, \u00c7elik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017;38:2183\u201391.","journal-title":"Eur Heart J"},{"key":"7585_CR2","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1001\/jama.2012.54506","volume":"308","author":"C M\u00e9rie","year":"2012","unstructured":"M\u00e9rie C, K\u00f8ber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308:2118\u201325.","journal-title":"JAMA"},{"key":"7585_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2012.05.029","volume":"60","author":"JM Brennan","year":"2012","unstructured":"Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database. J Am Coll Cardiol. 2012;60:971\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"7585_CR4","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","volume":"25","author":"M Heras","year":"1995","unstructured":"Heras M, Chesebro JH, Fuster V, et al. High Risk of Thromboemboli Early After Bioprosthetic Cardiac Valve Replacement. J Am Coll Cardiol. 1995;25:1111\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"7585_CR5","doi-asserted-by":"crossref","unstructured":"Zhang H, Dong Y, Ao X, Fu B, Dong L; CLIATHVR (Chinese Low Intensity Anticoagulant Therapy After Heart Valve Replacement) multicenter clinical study team. Comparison of antithrombotic strategies in chinese patients in sinus rhythm after bioprosthetic mitral valve replacement: early outcomes from a multicenter registry in China. Cardiovasc Drugs Ther. 2021;35:1\u201310.","DOI":"10.1007\/s10557-020-07069-8"},{"key":"7585_CR6","doi-asserted-by":"crossref","unstructured":"Russo A\u00a0,\u00a0Grigioni F,\u00a0Avierinos JF,\u00a0et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications.J Am Coll Cardiol. 2008;51:1203\u201311.","DOI":"10.1016\/j.jacc.2007.10.058"},{"key":"7585_CR7","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1253\/circj.CJ-20-0135","volume":"84","author":"C Izumi","year":"2020","unstructured":"Izumi C, Eishi K, Ashihara K, et al. JCS\/JSCS\/JATS\/JSVS 2020 guidelines on the management of valvular heart disease. Circ J. 2020;84:2037\u2013119.","journal-title":"Circ J"},{"issue":"143","key":"7585_CR8","first-page":"e35","volume":"2","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;2(143):e35\u201371.","journal-title":"Circulation"},{"key":"7585_CR9","doi-asserted-by":"publisher","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395.","DOI":"10.1093\/eurheartj\/ehab395"},{"key":"7585_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"7585_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"7585_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"7585_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","volume":"132","author":"A Avezum","year":"2015","unstructured":"Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132:624\u201332.","journal-title":"Circulation"},{"key":"7585_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","volume":"135","author":"AP Carnicelli","year":"2017","unstructured":"Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017;135:1273\u20135.","journal-title":"Circulation"},{"key":"7585_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/clc.23178","volume":"42","author":"PO Guimar\u00e3es","year":"2019","unstructured":"Guimar\u00e3es PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42:568\u201371.","journal-title":"Clin Cardiol"},{"key":"7585_CR16","doi-asserted-by":"crossref","unstructured":"Guimaraes HP, Lopes RD, de Barros e Silva PGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:2117\u201326.","DOI":"10.1056\/NEJMoa2029603"},{"key":"7585_CR17","first-page":"440","volume":"86","author":"C Izumi","year":"2022","unstructured":"Izumi C, Miyake M, Fujita T, et al. Antithrombotic therapy for patients with atrial fibrillation and bioprosthetic valves - real-world data from the multicenter, prospective. Observational BPV-AF Registry Circ J. 2022;86:440\u20138.","journal-title":"Observational BPV-AF Registry Circ J"},{"key":"7585_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.amjcard.2023.07.141","volume":"206","author":"M Suppah","year":"2023","unstructured":"Suppah M, Kamal A, Saadoun R, et al. An evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin k antagonists in patients with atrial fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol. 2023;206:132\u201350.","journal-title":"Am J Cardiol"},{"key":"7585_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40261-020-00939-x","volume":"40","author":"S Pasciolla","year":"2020","unstructured":"Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig. 2020;40:839\u201345.","journal-title":"Clin Drug Investig"},{"key":"7585_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jtcvs.2021.01.127","volume":"165","author":"CY Shim","year":"2023","unstructured":"Shim CY, Seo J, Kim YJ, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg. 2023;165:58\u201367.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"7585_CR21","first-page":"1222","volume":"160","author":"JP Beller","year":"2020","unstructured":"Beller JP, Krebs ED, Hawkins RB, et al. Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing. JTCS. 2020;160:1222\u201331.","journal-title":"JTCS"},{"key":"7585_CR22","first-page":"899","volume":"38","author":"K Gadsb\u00f8ll","year":"2017","unstructured":"Gadsb\u00f8ll K, Staerk L, Fosb\u00f8l EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38:899\u2013906.","journal-title":"Eur Heart J"},{"key":"7585_CR23","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1253\/circj.CJ-19-0094","volume":"83","author":"Y Koretsune","year":"2019","unstructured":"Koretsune Y, Yamashita T, Akao M, et al. Baseline demographics and clinical characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. Circ J. 2019;83:1538\u201345.","journal-title":"Circ J"},{"key":"7585_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026645","volume":"9","author":"G Maura","year":"2019","unstructured":"Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011\u20132016. BMJ Open. 2019;9: e026645. https:\/\/doi.org\/10.1136\/bmjopen-2018-026645.","journal-title":"BMJ Open"},{"key":"7585_CR25","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.jtcvs.2019.04.096","volume":"159","author":"WT Chang","year":"2020","unstructured":"Chang WT, Ho CH, Chang CL, Cheng BC, Wu NC, Chen ZC. Influence of warfarin on cardiac and cerebrovascular events following bioprosthetic aortic valve replacement: a nationwide cohort study. J Thorac Cardiovasc Surg. 2020;159:1730\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"7585_CR26","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMoa1509233","volume":"373","author":"RR Makkar","year":"2015","unstructured":"Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015\u201324.","journal-title":"N Engl J Med"},{"key":"7585_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"GD Dangas","year":"2020","unstructured":"Dangas GD, Tijssen JGP, W\u00f6hrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120\u20139.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07585-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:12:33Z","timestamp":1762881153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7585"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07585-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"21 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Izumi has received speaker honoraria from Daiichi Sankyo Co., Ltd, Nippon Boehringer Ingelheim and Novartis and research funding from Pfizer, LSI Medience Co, PPD-SNBL K.K, Abott Medical Japan, Bristol-Myers Squibb, and Eli Lilly and Company.The other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Daiichi Sankyo Co., Ltd. and the National Cerebral and Cardiovascular Center had entered into a research agreement before the study started. Daiichi Sankyo Co., Ltd. is not involved in the design, management, analysis, and reporting of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}